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a b s t r a c t
C-type natriuretic peptide (CNP) is a member of the small family of natriuretic peptides that also includes
atrial natriuretic peptide (ANP) and brain, or B-type natriuretic peptide (BNP). Unlike them, it performs
its major functions in an autocrine or paracrine manner. Those functions, mediated through binding
to the membrane guanylyl cyclase natriuretic peptide receptor B (NPR-B), or by signaling through the
non-enzyme natriuretic peptide receptor C (NPR-C), include the regulation of endochondral ossiﬁcation,
reproduction, nervous system development, and the maintenance of cardiovascular health. To date, the
regulation of CNP gene expression has not received the attention that has been paid to regulation of
the ANP and BNP genes. CNP expression in vitro is regulated by TGF-␤ and receptor tyrosine kinase
growth factors in a cell/tissue-speciﬁc and sometimes species-speciﬁc manner. Expression of CNP in vivo
is altered in diseased organs and tissues, including atherosclerotic vessels, and the myocardium of failing
hearts. Analysis of the human CNP gene has led to the identiﬁcation of a number of regulatory sites in the
proximal promoter, including a GC-rich region approximately 50 base pairs downstream of the Tata box,
and shown to be a binding site for several putative regulatory proteins, including transforming growth
factor clone 22 domain 1 (TSC22D1) and a serine threonine kinase (STK16). The purpose of this review
is to summarize the current literature on the regulation of CNP expression, emphasizing in particular
the putative regulatory elements in the CNP gene and the potential DNA-binding proteins that associate
with them.
Published by Elsevier Inc.
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1. Introduction – natriuretic peptides
The natriuretic peptides, atrial natriuretic peptide (ANP), brain
natriuretic peptide (BNP) and C-type natriuretic peptide (CNP)
constitute a family of small (22–53 amino acid) polypeptides, each
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of which contains a highly conserved 17-member ring structure
[47,59,69]. The founding member of the family, ANP, discovered in
the rat atrium and found to possess profound natriuretic properties
by de Bold in 1981 [19], is now known to play an important role in
maintaining cardiovascular and ﬂuid homeostasis [48]. BNP, synthesized primarily in the heart, not the brain, has similar actions.
However, circulating levels of this peptide are quite low in the
normal state and are only elevated (as much as 200–300-fold [69])
in chronic disease states, especially in diseases of the ventricular
myocardium in which transcription of the BNP gene is reactivated
[18].
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ANP is released into the circulation from atrial granules in
response to both mechanical and hormonal signals generated by
increased blood volume, and targets organs involved in ﬂuid regulation to lower blood volume and blood pressure [50,59]. Much of
the action of ANP is a result of its binding to one of a unique group of
membrane-bound guanylyl cyclases that catalyze the formation of
intracellular cGMP in target cells [30]. The two membrane-bound
guanylyl cyclases that act as natriuretic peptide receptors are designated as NPR-A and NPR-B (natriuretic peptide receptors A and
B, respectively). NPR-A is highly speciﬁc for both ANP and BNP;
NPR-B is selective for binding to CNP. Downstream effects of ANPinduced intracellular cGMP are mediated by activation of several
of the same protein kinases, phosphodiesterases, and channel proteins that transduce the actions of nitric oxide (NO) in target tissues
[69]. Therefore, the natriuretic peptides have been shown to perform many of the same functions as NO in tissues where both
signal molecules are expressed (e.g., in the vasculature). However,
all three natriuretic peptides also bind with high afﬁnity to a third
receptor, NPR-C, which is not a membrane guanylyl cyclase, but
a dimer without apparent enzymatic activity. Nonetheless, NPR-C
is capable of coupling natriuretic peptide binding to downstream
signaling pathways by interacting with G-proteins [4].

2. C-type natriuretic peptide
Two years after the discovery of its speciﬁc receptor, NPR-B
[42,74,75], the third natriuretic peptide was identiﬁed as a product of porcine brain in 1990 [79] and following the alphabetical
sequence established by the ﬁrst two natriuretic peptides was designated simply as ‘C-type’ natriuretic peptide. Unlike ANP and BNP,
both of which circulate at concentrations that are increased manyfold in response to hemodynamic alterations and cardiac diseases
such as congestive heart failure, plasma levels of CNP are low, and
show much smaller changes, or no change, with variations in blood
pressure and in diseases of the cardiovascular system [20,69,83,96].
These ﬁndings have helped establish the major functions of CNP as
being either paracrine or autocrine in nature, rather than endocrine.
In keeping with its limited range of action, CNP expression is normally conﬁned to those tissues and organs in which it exerts a
regulatory role, principally the brain and pituitary [82], cardiovascular system [11,23,38,69,98], endochondral bone [102], and the
male [100] and female [95,103] reproductive systems. CNP transcript and/or protein have also been identiﬁed in a number of
tissues and organs where its functional role has yet to be deﬁned
[9,76,77,94]. In contrast with ANP and BNP, whose speciﬁc actions
in the brain, kidney, cardiovascular system, and endocrine system
are collectively responsible for maintaining ﬂuid homeostasis, the
speciﬁc functions of CNP do not appear to be linked to any overarching physiologic role. Instead, CNP exerts several important but
unrelated actions in the body, including regulation of endochondral
ossiﬁcation, reproduction, nervous system function and development, and maintenance of cardiovascular health through regulation
of smooth muscle and endothelial function.
Over the past decade, one of the most clinically evident functions
of CNP has been recognized as its participation in the regulation
of long bone growth [6,29,66,102]. First discovered as a critical
factor in endochondral ossiﬁcation in CNP- or NPR-B knockout
mice exhibiting a phenotype of short stature and other skeletal
abnormalities [17,101], the CNP signaling system has since been
recognized as making an important contribution to the variation in
human height [5,27]. On the one hand, the cause of acromesomelic
dysplasia, type Maroteaux, a heritable condition associated with
short stature has been deﬁnitively shown to involve a mutation in
the NPR-B, the speciﬁc guanylate cyclase receptor for CNP [5]. Conversely, balanced translocations in chromosome 2 near the locus of
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the CNP gene (Nppc) resulting in excessive CNP production, may
be one of the factors contributing to the markedly tall phenotype
of certain Northern European populations [27].
Following the early ﬁnding of a role in regulating pituitary secretion [49,79], the CNP signaling system has since been identiﬁed as
having an elemental role in nervous system proper, including the
regulation of neuronal development and morphology in both the
central [55], and peripheral nervous systems [41,73,105]. CNP also
appears to intervene at several stages of the reproductive process,
ranging from the maintenance of oocytes in meiotic arrest in the
ovary [103], to the maintenance of normal erectile function in the
male through its vasodilatory action on cavernosal blood vessels
[92].
The mechanisms exploited by CNP to maintain erection [92],
speciﬁcally the NO-like activation of a cGMP signaling cascade, are
also used throughout the cardiovascular system to inhibit smooth
muscle contractility [75,98]. In addition, CNP has been proposed to
reduce vascular contractility using a novel mechanism of smooth
muscle hyperpolarization mediated via NPR-C, rather than NPR-B
[72,91].
Since CNP action is predominantly paracrine rather than
endocrine, however, it has not been shown to have the same systemic effect as ANP in lowering blood pressure [48], and is likely to
play a role in local (e.g. coronary circulation, or microcirculation)
rather than systemic control of blood ﬂow [3]. Another important
protective action of CNP in the cardiovascular system is its inhibition of the processes leading to cardiac and vascular remodeling and
ﬁbrosis after injury [80]. This action of CNP has been widely supported by both in vivo [36,45] and in vitro [7] studies and involves
the ability of CNP to inhibit myocyte hypertrophy (heart) or proliferation (smooth muscle), and to limit the ability of either tissue
type to synthesize matrix proteins after tissue damage.

3. Hormonal and pathophysiological determinants of CNP
gene expression
3.1. CNP regulation in the cardiovascular system
Unlike ANP, C-type natriuretic peptide is not stored in large
secretory granules that respond to appropriate signals with a
massive release of peptide [69]. Therefore, compared with other
members of the natriuretic family, the regulation of CNP function
is likely to be especially dependent on factors that regulate its transcription rather than its exocytosis. Furthermore, although CNP was
ﬁrst discovered in the mammalian brain, the early identiﬁcation
of CNP as product of endothelial cells coupled with the characterization of one of its receptors as a guanylyl cyclase [74] led to
the concept that endothelial CNP performs some of the same functions as NO in the vasculature. Like NO, endothelial CNP leads to
increased cGMP production in the underlying smooth muscle, and
consequently to the activation of vasoprotective cGMP-dependent
(e.g., protein kinase G) pathways downstream of that point [47]. In
view of its potential importance as an NO-like factor, many of the
initial studies of the hormonal and pathophysiologic alteration of
CNP production and secretion were focused on the endothelium.
One of the ﬁrst of these factors to be studied was TGF-␤, an
enhancer of CNP expression and secretion in endothelial cells
[63,83,84] that has since been shown to have a positive effect on
CNP transcript levels in rat [92] and human [52] vascular smooth
muscle cells. The stimulatory effect of TGF-␤ on vascular CNP production would suggest that this key agent in vascular remodeling
after injury could constitute part of a feedback loop limiting TGF␤-induced ﬁbrosis through the actions of CNP [83].
Tumor necrosis factor-␣ (TNF-␣) was found to be even more
effective than TGF-␤ at increasing immunoreactive CNP in endothe-
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lial cells [83], and interleukin-1 (IL-1) also had a smaller, though
still signiﬁcant effect on production of the peptide, suggesting that
macrophage association with endothelial cells as occurs in an area
of atheroma formation could result in increased production of the
vaso-protective CNP. A positive effect of direct macrophage interaction with endothelial cells on CNP transcription and secretion was
further supported in co-culture studies of these two cell types [85].
Several mechanisms regulating endothelial CNP expression may
be speciﬁc to this tissue type due to its constant exposure to blood
ﬂow and plasma content. These include an up-regulation of CNP
transcription by shear stress [16,104], and an increase in mRNA levels in human cells by the bioactive lipid, lysophosphatidylcholine,
in a process independent of intracellular calcium ﬂux [53]. Similarly, the observed suppression of endothelial CNP by vascular
endothelial growth factor (VEGF) might be speciﬁc to those cells,
such as endothelial cells, that express VEGF receptors in high concentration [26].
Another factor in plasma that has a positive effect on CNP transcript and protein levels in endothelial cells is ANP [58]. Acting
through activation of NPR-A and subsequent cGMP signaling, ANP
and BNP (whose effect was even greater than that of ANP) were
observed to increase CNP secretion as much as 20-fold, and steadystate levels of CNP mRNA by 2–3-fold [58]. This observation invites
speculation that the local effects of CNP in the vasculature are linked
to blood pressure and plasma volume through the other two members of the natriuretic peptide family.
In addition to its regulation by TGF-␤, CNP production in vascular smooth muscle cells has been shown to respond to treatment
with several growth factors in the tyrosine-kinase receptor growth
factor family. Some of these factors have exhibited remarkable variability in their effects on cardiovascular CNP expression in different
species and tissue types. For example, in cultured human aortic
smooth muscle cells (AoSMC), CNP mRNA levels were increased
as much as 50-fold by platelet-derived growth factor BB (PDGFBB) [51]. In rat-derived AoSMC however, CNP mRNA levels were
reduced to only 7% of their control value in the presence of PDGFBB [51]. Similarly, basic ﬁbroblast growth factor (bFGF) was shown
to suppress CNP transcript levels in cultured AoSMC derived from
the rat [97], but it elevated CNP transcript levels in cultured smooth
muscle cells derived from the human aorta [51]. On the other hand,
CNP transcript levels responded positively to basic ﬁbroblast bFGF
in smooth muscle cells derived from human aorta, but showed no
response to bFGF in human coronary-artery derived smooth muscle cells [52]. Studies such as these underscore the importance
of cell phenotype and even species differences in delineating the
intracellular transduction pathways controlling CNP production.
3.2. CNP regulation in cardiovascular disease
A number of reports have noted changes in CNP expression
occurring in cardiovascular disease, some of which could reﬂect
alterations in autocrine/paracrine regulatory factors accompanying
disease progression. Naruko et al. [57] used immunohistochemistry
to compare CNP expression in normal coronary artery (i.e., having
only diffuse intimal thickening) with expression in coronary arteries possessing atherosclerotic lesions of increasing severity. Results
showed CNP immunoreactivity conﬁned mostly to endothelial
cells in arteries possessing only diffuse intimal thickening, but in
endothelium overlying more advanced (hypercellular) lesions and
in the most advanced lesions (ﬁbrous, ﬁbro-lipid, and lipid-rich
plaques), endothelial CNP positivity was greatly reduced. In contrast, immunoreactive CNP in smooth muscle cells increased with
atherosclerotic progression through the hypercellular stage, but
decreased in the most advanced lesions. This observation would
suggest the existence of cell type-speciﬁc differences in the regulation of vascular CNP expression. Subsequently, in a rat model

of neointima formation following balloon angioplasty, Brown et al.
[8] noted that CNP is expressed in SMC that have invaded and proliferated in the neointima, but not in SMC in the adjacent media
or in uninjured arteries. A study of CNP expression in human
neointimal SMC following angioplasty [56] pointed to a similar,
time-dependent up-regulation of CNP in the human SMC that was
maintained for at least six months after surgical intervention. Casco
et al. [11], using immunohistochemistry, identiﬁed CNP in both
medial and intimal SMC of early through advanced atherosclerotic lesions, but the relationship of CNP to lesion stage was not
described. CNP expression has also been studied in human aortic valves with increasing severity of stenosis, a condition that
has many of the hallmarks of atherosclerosis, including early
inﬂammation and later ﬁbrosis and calciﬁcation [68]. The authors
showed a signiﬁcant (92%) decrease in CNP mRNA in stenotic aortic
valves compared with valves from patients with aortic regurgitation, a milder form of the disease. Histologically, CNP expression
was localized in valvular endothelial cells, myoﬁbroblasts and
stromal cells. Taken together, these studies indicate a shifting pattern of CNP expression during the progression of atherosclerotic,
restenotic and valvular lesions, characterized by an overall reduction in endothelial CNP and an increase in CNP in other cell types,
such as neointimal SMC. Such observations are consistent with a
role for smooth muscle CNP in controlling ﬁbrosis and SMC proliferation after vascular damage, possibly induced by the same
cytokines (TGF-␤, PDGF, FGF) that trigger neointimal growth following endothelial denudation.
In diseases of the myocardium such as heart failure, it has been
clearly established that both ANP and BNP expression in the heart
are markedly increased, and in the case of BNP, up-regulation of
plasma BNP is of such magnitude that assays for this peptide are
now routinely used to establish the presence and severity of congestive heart failure (CHF) [50,71]. In contrast, plasma levels of CNP
or its amino terminal marker have not shown consistent elevations
in human CHF, with some studies showing no difference between
control and CHF [10,89,96], and others showing small, but signiﬁcant increases in heart failure ranging from an ∼50% increase
[21] to a ∼4-fold increase in heart failure of the highest clinical
severity [24]. Plasma CNP levels have also been reported as signiﬁcantly elevated (3.2-fold) in patients with cor pulmonale (right
ventricular hypertrophy) [10], and in patients with left ventricular dysfunction irrespective of overt heart failure [22]. Moreover, a
study that assessed speciﬁcally the myocardial production of CNP
in heart failure patients by comparing arterial levels with levels in
the coronary sinus, showed signiﬁcant correlation of patient CNP
level with pulmonary capillary wedge pressure [37]. Studies of CNP
expression in experimentally induced heart failure in sheep [12]
using trans-organ arteriovenous sampling (comparison of carotid
artery CNP with CNP in various venous beds) found small, but signiﬁcant increases in plasma CNP in animals with heart failure. In a
study of heart failure in pigs [20], plasma CNP was increased about
2-fold by one week of pacing-induced heart failure, and left ventricular CNP mRNA was increased by ∼3-fold over control but did
not attain signiﬁcance [20]. Changes in cardiac CNP expression have
also been examined in diabetic cardiomyopathy in a genetic mouse
model of the disease (ob/ob genotype). No difference was found
in expression levels of cardiac CNP mRNA between the diabetic
ob/ob mice and heterozygous controls, despite a greater than 10fold difference in plasma insulin levels between the diabetic and
non-diabetic groups [15]. However, NPR-B expression levels were
signiﬁcantly elevated in the diabetic model, suggesting that diabetes might enhance cardiac sensitivity to CNP despite causing no
change in CNP expression.
The results of most of the aforementioned studies suggest that
despite the recognized importance of CNP in reducing cardiac ﬁbrosis in diseased hearts [80], myocardial CNP expression itself, unlike
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ANP and BNP, is not greatly altered in response to cardiac disease. A possible explanation of these results is that cardiac CNP
is not expressed primarily in myocytes, but in the smaller population of cardiac ﬁbroblasts, whose overgrowth and extracellular
matrix production are responsible for cardiac ﬁbrosis in pathological states [34]. In support of this hypothesis, Horio et al. [34] in
an in vitro study of the secretory response of these cardiac ﬁbroblasts to several hormones and cytokines, found that ﬁbroblasts, but
not myocytes, expressed CNP mRNA and that they secreted significantly more CNP in the presence of TGF-␤ or bFGF than they did
with control medium. It is also possible that heart-failure induced
changes in CNP expression could reﬂect changes occurring primarily in endothelial or smooth muscle expression of the peptide,
rather than in the cardiac myocyte.

Also in stark contrast to the mouse macrophages [93], phorbolester treatment increased CNP secretion as high as 20-fold in a
human macrophage-like leukemia cell line. Whether the contrasting responses of mouse and human leukocyte-derived cells to LPS
and to phorbol esters owes more to differences in phenotype or to
species differences is a matter for further investigation. However if
the manner of CNP regulation in a given cell type is shown to vary
between species, it is conceivable that the difference may reside in
the structure of the CNP gene itself, especially in the sequence of
its 5 promoter. This region has been examined in several studies,
described below.

3.3. CNP regulation in other tissues and organs

The gene encoding human C-type natriuretic peptide (Nppc)
was sequenced shortly after the discovery of the peptide [61,87].
Like the genes for ANP and BNP, Nppc has been shown to be composed of three exons, the ﬁrst two encoding a 126 amino acid
pre–pro peptide that contains the two active forms of CNP; a
22-amino acid, and a 53-residue form designated as CNP-22 and
CNP-53, respectively. Unlike ANP and BNP, neither form of CNP
possesses a carboxy-terminal extension [69]. A third peptide, NTpro-CNP, derived from the N-terminal of the pre–pro peptide has
no known function, but circulating at higher levels than either CNP22 or CNP-53, it serves as a convenient serum marker of changes
in active CNP in response to endocrine alterations and disease
[12,25,65]. The proximal 5 -ﬂanking region of the gene was found
to contain two GC-boxes (Sp-1 binding sites) in tandem in addition to several other cis elements including an inverted CCAAT box
(Y box), and a CRE-like (cAMP response-like) element within 50 bp
upstream of a Tata box (TATAAA) [62,63,90]. These sequences have
been hypothesized to constitute potential targets in the regulation
of CNP expression, and are not present in the promoter regions of
either the ANP or BNP genes [87].
A detailed functional analysis of the proximal promoter region
in the human CNP gene [62] extending to approximately 1400 bp
upstream of the transcription start site, demonstrated the existence of a positive regulatory region between positions −54 and
−19, a sequence encompassing the tandem GC-boxes. In addition,
at least two negative regulatory regions were identiﬁed much further upstream. Mutation analysis showed furthermore that 90% of
the positive regulatory activity for CNP expression resides in the
GC-rich region containing the two GC-boxes. Ogawa et al. [60] then
compared the human CNP gene with its mouse equivalent, and
found both some interesting similarities and differences between
the two. The 5 -ﬂanking regions through about 130 bp upstream
of the transcription start site of both CNP genes were shown to
have several putative cis-acting regulatory elements in common,
including a Y-box, a putative CRE-like sequence, and a GC box
[60]. However, the human promoter lacks several of the regulatory elements found in the mouse promoter, including a long CA
repeat region further upstream and a nuclear transcription factor
␤ (NF-␤) recognition site present in the mouse. This last observation is particularly interesting in light of the reported mouse vs.
human differences in CNP response to LPS since the bacterial protein is known to signal through the NF-␤ pathway [95]. In addition,
although both species possess at least one GC box in the promoter,
the human CNP promoter possesses two GC boxes in tandem to constitute the ‘GC-rich’ DNA-binding site as described above [62]. This
could represent a crucial difference in CNP transcriptional regulation between rodent and human. As an example, it has been shown
[40] that a Kruppel-like zinc ﬁnger transcription factor (Zf9) binds
to two tandem GC-boxes in the TGF-␤1 promoter with high afﬁnity to up-regulate TGF-␤ transcription, but to a single GC box with
much lower afﬁnity. In addition, Kf9 selectively activates genes

Regulation of CNP expression has also been studied in several
other CNP target systems, where the observed responses could
either reﬂect a general pathway for CNP gene regulation, or could be
restricted to a speciﬁc tissue or cell type. In chondrocytes, a major
cellular target of CNP involved in long bone growth, glucocorticoid (dexamethasone) was found to increase the expression of CNP
mRNA almost 4-fold [2], suggesting the possibility of a CNP role in
modulating the effects of glucocorticoid on endochondral ossiﬁcation. Using plasma levels of amino-terminal pro CNP (NT-proCNP)
as a biomarker for hormonal regulation of CNP in the cartilage
growth plate, Olney et al. [65] showed evidence that the positive
effects of growth hormone and testosterone on bone growth at
puberty could be due in part to their up-regulation of CNP production in the growth plate at this time. Also using NT-proCNP as
a plasma biomarker of CNP synthesis, Prickett et al. [70] showed
that exogenous estradiol administered to female lambs and adult
sheep signiﬁcantly increased CNP expression compared with control animals. The source of the elevated CNP, while not deﬁnitively
identiﬁed, was thought likely to be derived from osteoblasts in bone
tissue [70]. In marked contrast to the ﬁnding of a positive relationship between testosterone and CNP in pre-pubertal boys [65],
Prickett et al. observed no effect of testosterone administration on
CNP in male lambs, a species difference in CNP regulation that the
authors speculated could be related to the timing of testosterone
intervention and the stage of pubertal maturation [70]. These studies point to the possibility that the inﬂuence of steroids on bone
growth could be mediated, at least in part, through their regulation
of CNP synthesis.
Gonadal steroids have also been proposed in the regulation of
CNP expression in the female reproductive system, where it was
shown that uterine CNP expression in mice varies during the estrus
cycle [35], and that pregnancy increases uterine CNP mRNA up to
7-fold [81]. Furthermore, uterine CNP and CNP transcription were
observed to increase with the administration of exogenous estradiol to ovariectomized mice [1]. A steroid hormone-responsive
consensus sequence has not yet been identiﬁed in the CNP promoter [70,89], suggesting that the observed effects of steroids on
CNP expression could be secondary to their effects on the transcription of other proteins.
Another potentially important regulator of CNP expression as
judged by the magnitude of its effect is bacterial lipopolysaccharide
(LPS), which increased CNP mRNA up to 300-fold, and immunoreactive CNP secretion 10-fold in mouse macrophages [93]. Phorbol
ester and dexamethasone, in contrast, had no effect. Kubo et al.
[43], studying human macrophages in culture, however, found only
a modest increase of CNP (25%) in one macrophage cell line, and
no change in another cell line after LPS treatment. Similarly, LPS
had no effect on CNP secretion from human granulocytes, lymphocytes, monocytes or monocyte-derived macrophages in culture.

4. CNP gene
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with tandem GC-boxes, but represses genes with a single GC box. It
therefore appears possible that either Kf9, or another DNA-binding
protein speciﬁc for tandem GC could selectively activate the human
CNP gene, and repress the rodent gene. These human-rodent differences together with the presence or absence of putative regulatory
elements in both the single intron and the 3 -untranslated region
identiﬁed in one species or the other, could account for some
of the species-speciﬁc regulation of the CNP gene that has been
observed.

5. Putative transcription factors
Based on the similarity of speciﬁc sequences in the CNP proximal
promoter to consensus sequences for the ubiquitous transcription
factor Sp-1 and CRE binding protein (CREB), these two transcription
factors were among the ﬁrst to be examined as potential regulators of CNP transcription. Ohta et al. [62] found, however, that
neither the Sp-1 nor the CREB consensus binding sequence was
able to compete effectively with the GC-rich region of human Nppc
for binding of nuclear protein. The consensus sequence for Ap-2
was similarly without effect. Furthermore, a 70 kD putative regulatory protein, identiﬁed by its binding to the GC-rich region, did not
match the MWs for either Sp-1, CREB or Ap-2 [62]. On the contrary,
Thompson et al. [88] have very recently shown evidence using electrophoretic mobility shift assays (EMSA) that both Sp-1 and Sp-3
bind as a complex to the putative GC-rich regulatory site in the
proximal Nppc promoter. It might be worth noting that although
both studies employed nuclear extract from pituitary cell lines or
the pituitary proper, the CNP gene examined in the Ohta et al. study
was human, but the gene in the Thompson et al. study was from
the mouse [88].
Ohta et al. [63] continued the search for CNP transcription factors using Southwestern screening of a rat pituitary cell-derived
library for the ability to bind the GC-rich sequence in the human
CNP promoter. Their results identiﬁed TSC22D1 (transforming
growth factor ␤ clone, domain 1), the founding member of a small
family of evolutionarily conserved leucine zipper proteins that perform a diverse array of functions in mammalian cells [28,31] as a
protein that binds to the human CNP promoter. Although initially
cloned using binding to a GC-rich element in the CNP promoter
as a selection criterion [63] and despite its leucine zipper-like
motif, TSC22D1 lacks the conventional DNA-binding domain of the
leucine zipper transcription factors [78]. Therefore its proposed
role as a direct enhancer of CNP transcription has remained in
question. Recent studies in our laboratory using siRNA gene silencing techniques have shown that TSC22D1-silencing signiﬁcantly
reduces both PDGF-up-regulated CNP transcript in human aortic
SMC and TGF-␤-up-regulated transcript in coronary artery-derived
SMC [52]. These results suggest that in human vascular smooth
muscle cells, TSC22D1 expression and activity could represent a
critical element in a ﬁnal common pathway leading to increased
CNP expression induced by different stimuli.
Whether TSC22D1 binds directly to promoter DNA, or is instead
part of an active regulatory complex remains to be resolved. Several
studies support the latter possibility. In a study of the induction of
erythroid differentiation, evidence was presented suggesting that
TSC22D1 can bind to and modulate the transcriptional activity of
two proteins, Smad 3 and Smad 4 that are important in TGF-␤ signal
transduction [14]. Another possible mechanism by which TSC22D1
could regulate gene transcription is its formation of homo- and
heterodimers with other members of the TSC22 domain family to
form complexes with different transcriptional activity compared
with TSC22D1 acting alone [39]. Determination of a speciﬁc mechanism of action of TSC22D1 in regulating CNP transcription is
further complicated by the existence of TSC22D1 splice variants

that result in the formation of proteins of very different MW (18 kD
vs. >100 kD) [28]. Recent studies [31,99] suggest that these protein
variants could perform unrelated, or even antagonistic functions in
the mammalian cell; e.g., although the short form of TSC22D1 has
been described many times as a tumor suppressor, the long form
in contrast promotes proliferation, growth and cell survival [99].
Interestingly, in our recent studies of the effects of TSC22D1 silencing on CNP expression in vascular smooth muscle cells, [52], we
could only identify a long form of the protein (∼120 kD) in Western blots, yet the downregulation of this protein with TSC22D1
siRNA resulted in reduced production of CNP transcript in these
cells.
Additional cellular functions of TSC22D1 that have been recently
posited include the initiation of apoptosis [46] and the induction
of contact inhibition [44], both of which functions may contribute
to its postulated role as a tumor suppressor [33]. TSC22D1 also
remains a potentially signiﬁcant factor in cardiovascular ﬁbrosis,
since it has been identiﬁed as one of only four transcription-related
genes that were up-regulated in a pacing-induced model of atrial
ﬁbrillation, a condition that can result in cardiac ﬁbrosis [13].
Using the same methodology that they had used earlier to clone
transcription factors capable of binding the GC-rich element of the
CNP promoter, Ohta et al. [64] identiﬁed a second putative CNP
activator as a novel protein with both DNA-binding ability and
serine-threonine kinase (STK) activity. This protein, designated as
TSF-1 by its discoverers and later as STK16, appears to be localized
to the Golgi apparatus, but can translocate to the nucleus and modulate the activation of the VEGF gene [32]. It is noteworthy that the
VEGF gene possesses a GC-rich putative regulatory sequence in its
proximal promoter that is very similar to the GC-rich sequence in
the CNP promoter that has been proposed as a binding site for both
STK16 [64] and TSC22D1. Aside from this initial report [64], there
have been no further studies of STK16 as a transcriptional regulator
of CNP. However, a recent report of CNP overexpression and long
bone overgrowth in patients with chromosomal translocations in
a region (2q37) in the vicinity of the STK16 gene raises the possibility that this CNP-induced overgrowth could be associated with
a dysregulation of STK16 expression [54].
More recently, the Wnt4/␤-catenin system has been proposed
as a transcriptional regulator of CNP in rodent kidney, an organ in
which induction of Wnt-4 expression is critical in genitourinary
development, and is re-induced following unilateral uretal ligation
[86]. The authors of this report noted that cells expressing Wnt4 in the obstructed kidney also expressed CNP, and hypothesized
that increased Wnt-4 protein acting through ␤-catenin and DNAbinding proteins of the T cell factor/lymphoid enhancer binding
factor (TCF/LEF) family activated CNP transcription. Their argument
was supported by studies showing that six hypothetical TCF/LEF
binding sites are present in the mouse CNP proximal promoter,
and that two of these sites are crucial for the activation of a CNP
transgene by the Wnt-4 signaling pathway. This study is interesting in showing that sites other than the GC-rich region of the CNP
promoter can play an important role in regulating CNP expression.
Whether this hypothetical Wnt/B-catenin/CNP pathway is speciﬁc
for renal tissue, and whether it functions in the human as well as
the rodent kidney remains to be determined.
Another possible CNP transcription factor, one speciﬁcally
involved in the ﬂow-dependent regulation of gene expression in
human endothelial cells, has been identiﬁed as Kruppel-like factor
2 (KLF-2) [67]. Blockade of ﬂow up-regulated KLF-2 expression signiﬁcantly reduced the expression of several ﬂow-regulated genes,
including CNP, suggesting that KLF-2 could potentially mediate the
ﬂow-mediated increases in CNP production in vivo that have been
described [16,104]. Whether KLF-2 bears any afﬁnity to KLF-9 in
binding to a tandem GC-box in preference to a single GC-box has
yet to be determined.
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6. Conclusion
Twenty years after the discovery of CNP and its subsequent identiﬁcation as a paracrine/autocrine-acting member of the natriuretic
peptide family in the cardiovascular and other organ systems, the
regulation of CNP transcription remains far from being completely
understood. It therefore constitutes a fruitful area for investigation of new therapies targeting CNP production in the treatment
of disease. For example, up-regulated CNP acting through cGMP
could fulﬁll vasodilatory and antiﬁbrotic functions in the vasculture
very similar to NO, but without incurring the deleterious effects
of NO oxidation products. Similarly, diseases of bone growth can
potentially be treated by novel means of CNP up-regulation that circumvent the risks of more commonly used hormone replacement
therapies.
Studies to date have identiﬁed a number of potential regulator
sequences in the CNP gene and a handful of transcriptional regulators such as TSC22D1 that may be involved in CNP regulation
at the level of its 5 promoter, but crucial details of the regulatory
pathways that lead to suppression of or up-regulation of CNP transcription remain unknown. Understanding how those transduction
pathways lead to increased CNP transcription in tissues and organs
of clinical relevance is a subject worthy of further investigation.
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